Related Experiment Video
Updated: Oct 12, 2025
06:34
A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
Published on: March 27, 2017
12.1K
In vitro Aggregation Ability of Five Commercially Available Aβ42 peptide
Zhaoji Lv1, Xi Du1, Zhongsheng Chen1
1Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu,China.
Current Alzheimer Research
|November 25, 2021
Summary
Synthetic human Amyloid-β (1-42) peptide aggregation varied significantly between manufacturers. This inconsistency impacts Alzheimer's disease research reliability, highlighting the need for standardized Aβ42 evaluation methods.
Area of Science:
- Biochemistry
- Neuroscience
- Materials Science
Background:
- Synthetic human Amyloid-β (1-42) (Aβ42) peptide is a fundamental research material.
- Consistent aggregation ability of Aβ42 is crucial for reliable Alzheimer's disease studies.
- Previous evaluations of commercial Aβ42 peptide aggregation consistency are lacking.
Purpose of the Study:
- To assess and compare the aggregation consistency of five commercially available Aβ42 peptides.
- To identify variations in the aggregation kinetics and properties of different Aβ42 sources.
- To underscore the importance of evaluating Aβ42 peptide aggregation for research reproducibility.
Main Methods:
- Five distinct Aβ42 peptides (A-E) were pretreated with HFIP.
- Aggregation kinetics were monitored using Thioflavin T (ThT) assay over 30 hours.
- Post-aggregation analysis included ThT fluorescence, circular dichroism (CD), SDS-PAGE, Western blot, transmission electron microscopy (TEM), and cytotoxicity assays (CCK-8).
Main Results:
- Significant differences in aggregation kinetics were observed; peptides B and D showed sigmoidal curves, while A, C, and E exhibited lower aggregation levels.
- Peptides B and D demonstrated higher ThT fluorescence and distinct CD spectra compared to A, C, and E.
- Structural analysis revealed variations in aggregate formation (protofibrils vs. spherical aggregates) and oligomer distribution (dimers, trimers) among the peptides, with differential cytotoxicity observed.
Conclusions:
- Commercially sourced Aβ42 peptides exhibit substantial variability in aggregation properties.
- Discrepancies in aggregation assays necessitate the development of standardized measurement strategies for Aβ42.
- Attention to Aβ42 source variability is critical for advancing Alzheimer's disease research.
